Table 4

Influence of shortage/expected shortage of tocilizumab on treatment decisions in rheumatoid arthritis and giant cell arteritis

Influenced decision to start tocilizumab de novo
Rheumatoid arthritisGiant cell arteritis
No influence599 (85%)No influence614 (93%)
Preference of another bDMARD/tsDMARD76 (11%)Preference of MTX or another csDMARD24 (4%)
Postponement of treatment with TCZ32 (5%)Postponement of treatment with TCZ19 (3%)
Sarilumab used off-label6 (1%)
Influenced decision to modify treatment with tocilizumab in patients with stable disease
No influence683 (74%)No influence709 (90%)
Switch of intravenous to subcutaneous TCZ191 (21%)Switch of intravenous to subcutaneous TCZ65 (8%)
Prolongation of administration interval28 (3%)Prolongation of administration interval10 (1%)
Change of TCZ to another DMARD5 (0.6%)Change of TCZ to another DMARD2 (0.3%)
Change of TCZ to sarilumab18 (2%)Stopped treatment with TCZ2 (0.3%)
  • *Total number of answers to this question.

  • MTX; methotrexate; b, biological; cs, conventional synthetic; DMARD, disease modifying anti-rheumatic drug; TCZ, tocilizumab; ts, targeted synthetic.